Manufacturing Decisions That Shape mRNA Clinical Success

• Confusing your platform with solid ground can lead to clinical stumbles
• Yield that ignores RNA integrity or impurity directly reduce potency or increase reactogenicity
• Capping efficiency and the Poly-A tail are clinical levers, not just a spec

Speakers:

Scott Alderucci

Director of Process Development

Curia Global, Inc.